A precision medicine framework, matching drug to patient based on genetic, biomarker, and metabolic profiles, may eventually guide treatment decisions
Glucagon receptor agonism increases energy expenditure, which is why retatrutide produces more weight loss than tirzepatide at matched doses despite similar GLP-1/GIP activity
"This marks a breakthrough in field of weight management," Sciwind Biosciences, from which Pfizer licensed mainland China commercialisation rights in February, said on its website
Unfortunately, the drug is usually prescribed in a higher dose when used for weight loss, possibly increasing the risk that a patient will develop severe side effects such as gastroparesis, malnutrition-related disorders, deep vein thrombosis, and bowel obstruction